

# ZOGENIX

## New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 69th Annual American Epilepsy Society Meeting

November 25, 2015

*Three Poster Presentations will Highlight Efficacy, Cardiovascular Safety and Mechanism of Action of Low-Dose Fenfluramine in the Treatment of Dravet Syndrome*

*Zogenix will also Host a Scientific Exhibit Room: "History of the Use of Low-dose Fenfluramine in Pediatric Epilepsy"*

SAN DIEGO, Nov. 25, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the presentation of clinical and scientific posters, and the hosting of a scientific exhibit room at the 69<sup>th</sup> Annual American Epilepsy Society Meeting, which will take place in Philadelphia, PA, from December 4 - 8, 2015.

One poster will report efficacy data from a new cohort of 7 patients treated with ZX008 (low-dose fenfluramine) for Dravet syndrome. A second poster will focus on the evaluation of cardiovascular safety related to the treatment of the same 7 patients. A third poster reports on investigations into the mechanism of action for fenfluramine as a treatment for Dravet syndrome using a gene knockout zebrafish model.

In addition, on Monday, December 7, 2015, from 8:00 AM – 11:00 AM, Zogenix will host the "History of the Use of Low-dose Fenfluramine in Pediatric Epilepsy: An Intriguing Past, Present, and Future" in a Scientific Exhibit room highlighting all of the posters and publications focused on low-dose fenfluramine as a potential treatment for Dravet syndrome generated to date.

Zogenix expects to initiate Phase 3 clinical studies for ZX008 in 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome.

### **Zogenix at the 69<sup>th</sup> Annual American Epilepsy Society Meeting**

**Title: Low-dose Fenfluramine Significantly Reduces Seizure Frequency in Dravet Syndrome: A Prospective Study of a New Cohort of Belgian Patients**

**Date:** Poster Session 2, December 6, 2015

**Poster Session #:** 2.262

**Title: Cardiovascular Side Effects of Low-dose Fenfluramine Treatment in Dravet Syndrome: A Prospective Echocardiographic Pilot Study**

**Date:** Poster Session 2, December 6, 2015

**Poster Session #:** 2.266

**Title: Exploring the Mechanism-of-action of Fenfluramine, an Anti-Epileptic Drug in the Treatment of Dravet Syndrome, Using an *scn1Lab* Mutant Zebrafish Model**

**Date:** Poster Session 3, December 7, 2015

**Poster Session #:** 3.039

### **Fenfluramine Scientific Exhibit**

**Date:** December 7, 2015

**Time:** 8:00 AM – 11:00 AM

**Room:** 202A

### **About Zogenix**

Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit [www.zogenix.com](http://www.zogenix.com).

CONTACT: Investors: Andrew McDonald  
Founding Partner, LifeSci Advisors LLC  
646-597-6987 | [Andrew@lifesciadvisors.com](mailto:Andrew@lifesciadvisors.com)

Zogenix, Inc.